| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03996369 | Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis | PHASE3 | COMPLETED | 354 | — | — | Sep 1, 2020 | Dec 1, 2021 | Dec 20, 2022 | - | — |
| NCT03945188 | Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis | PHASE3 | COMPLETED | 433 | — | — | Jun 1, 2019 | Feb 1, 2022 | Dec 19, 2022 | - | — |
| NCT04706793 | Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN) | PHASE3 | COMPLETED | 42 | — | — | Dec 25, 2020 | Aug 3, 2022 | Oct 16, 2023 | 38 | Japan |
| NCT03950232 | An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis | PHASE3 | ACTIVE NOT_RECRUITING | 896 | — | — | Sep 5, 2019 | Jun 19, 2029 | May 11, 2026 | 211 | United States, Australia +29 |
| NCT02536404 | Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis | PHASE2 | COMPLETED | 118 | — | — | Jan 1, 2016 | Oct 1, 2018 | Nov 25, 2021 | - | — |
| NCT02447302 | Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis | PHASE2 | COMPLETED | 156 | — | — | Oct 1, 2015 | Feb 1, 2018 | Apr 4, 2021 | - | — |
| NCT05287126 | A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis | PHASE2 | RECRUITING | 36 | — | — | Dec 16, 2022 | Jul 10, 2033 | Jun 8, 2026 | 46 | United States, Belgium +4 |
| NCT05061446 | Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis | PHASE2 | COMPLETED | 54 | — | — | Sep 10, 2021 | Oct 6, 2023 | Oct 29, 2024 | 80 | Japan |
| NCT04607837 | Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis | PHASE2 | COMPLETED | 234 | — | — | Apr 12, 2021 | Jun 19, 2024 | Jul 15, 2025 | 288 | United States, Australia +16 |
Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
Safety as assessed by the evaluation of adverse events
Clinical remission:Participants with stool frequency (SF)subscore=0(or of 1 with greater than or equal to(\>=)1 point decrease from baseline,rectal bleeding(RB)subscore=0 and endoscopic score(ES)less than or equal to(\<)=1(excluding friability).SF subscore:number of stools in 24-hours relative to normal number of stools for that participant in same period,score ranged from 0(normal number of stools) to 3(5 or more stools than normal),higher scores=more severity.RB subscore:most severe amount of blood passed per rectum in 24-hours,score ranged from 0(no blood seen)to 3(blood alone passes),higher scores=more severity.ES:reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy,score ranged from 0(normal or inactive disease) to 3(severe disease \[spontaneous bleeding,ulceration\]),higher scores=more severity.Modified Mayo score:measure disease activity for UC,score:0(normal) to 9(maximum severity),comprised subscores for SF,RB,ES.higher score=more severe disease activity.
MMS is used to assess disease activity in participants with UC and has following components: endoscopic score(ES),rectal bleeding(RB),stool frequency(SF).Each component score ranges from 0 to 3(0=normal,1=mild,2=moderate,3=severe); higher scores indicating more severe disease.ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy,scores ranged from 0(normal or inactive disease) to 3(severe disease \[spontaneous bleeding, ulceration\]).RB reported most severe amount of blood passed per rectum in 24-hour period,scores ranged from 0(no blood seen) to 3(blood alone passes).SF reported number of stools in 24-hour period relative to normal number of stools for that participant in same period,scores ranged from 0(normal number of stools) to 3(5 or more stools than normal).CR per FDA draft guidance defined as:SF=0 or 1 and no greater than baseline, RB=0,ES less than or equal to (\<=)1(excluding friability).Percentage of participants achieving CR at Week 52 was evaluated.
| Arm | Type | Description |
|---|---|---|
| Etrasimod 2 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Etrasimod | EXPERIMENTAL | - |
| Etrasimod Dose 1 | EXPERIMENTAL | - |
| Etrasimod Dose 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Etrasimod | DRUG | Etrasimod 2 mg tablet by mouth, once daily up to 12-Week Induction Treatment Period |
| Placebo | DRUG | Etrasimod matching placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period |
Inclusion Criteria: Participants with moderately to severely active ulcerative colitis (UC) are eligible to enroll into this study if they fulfill all of the following: * Must have completed the Week 12 visit of Study APD334-302 * Ability to provide written informed consent or assent (parent or le...